{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dynamic+contrast-enhanced+magnetic+resonance+imaging&page=2", "query": { "intervention": "dynamic contrast-enhanced magnetic resonance imaging", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 157, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dynamic+contrast-enhanced+magnetic+resonance+imaging&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dynamic+contrast-enhanced+magnetic+resonance+imaging&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T16:36:15.203Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03121300", "title": "Functional Imaging in Lung SBRT", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "CT Scan", "type": "OTHER" }, { "name": "Lung CT", "type": "OTHER" }, { "name": "MRI", "type": "OTHER" }, { "name": "Walk Test", "type": "OTHER" }, { "name": "SGRQ", "type": "OTHER" }, { "name": "Biological Sample Collection", "type": "OTHER" }, { "name": "Toxicity", "type": "OTHER" }, { "name": "Cardiac Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2017-02-06", "completion_date": "2019-08-30", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03121300" }, { "nct_id": "NCT01799135", "title": "Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "DCE-MRI scan", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "4D-CT scan", "type": "OTHER" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-11", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01799135" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" }, { "nct_id": "NCT01223248", "title": "Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Ovarian Cancer", "Sarcoma", "Bone", "CNS-Spinal CD/MEMBR, NOS", "Lymph Nodes", "Soft Tissue" ], "interventions": [ { "name": "IGIMRT using a single dose of 24 Gy", "type": "RADIATION" }, { "name": "IGIMRT 27 Gy in 3 fractions", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2010-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 2, "location_summary": "San Francisco, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223248" }, { "nct_id": "NCT00450879", "title": "Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450879" }, { "nct_id": "NCT02526511", "title": "Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Arterial Spin Labeling Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Perfusion Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2015-04", "completion_date": "2023-09", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02526511" }, { "nct_id": "NCT01599832", "title": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2012-06", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 4, "location_summary": "Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01599832" }, { "nct_id": "NCT00659126", "title": "Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Primary Brain Neoplasm" ], "interventions": [ { "name": "3 Tesla Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "Gadolinium", "type": "DRUG" }, { "name": "High Field Strength Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Susceptibility Weighted Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-11-16", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2023-09-07", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659126" }, { "nct_id": "NCT05384535", "title": "Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer", "Magnetic Resonance Imaging", "Population at Risk" ], "interventions": [ { "name": "Bi-parametric MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "40 Years to 55 Years · Male only" }, "enrollment_count": 100, "start_date": "2022-08-15", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384535" }, { "nct_id": "NCT00103038", "title": "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Central Nervous System Lymphoma", "Malignant Glioma", "Metastatic Malignant Neoplasm in the Brain" ], "interventions": [ { "name": "3 Tesla Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "Gadolinium", "type": "DRUG" }, { "name": "MRI-Based Angiogram", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2004-06-04", "completion_date": "2016-06-10", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-12T16:36:15.203Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103038" } ] }